GLPwatch
Papers (10410)
Page 149 of 174, ranked by citation count.
- Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.
- Retatrutide.
- Linking GLP-1 activation with steroidogenesis, redox, endoplasmic reticulum stress, mitophagy, and the apoptotic regulatory network unlocks the emerging impacts of semaglutide on 5-fluorouracil-induced testicular toxicity.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Liraglutide: Weight loss injection is effective in children aged 6-11, study reports.
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
- [Effects of exenatide lar in type 2 diabetes mellitus and obesity].
- Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.
- Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome.
- Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.
- Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.
- ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine.
- Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Alcohol Use Disorder: Current Evidence and Future Directions.
- Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.
- Acute Duodenal Ulcer Perforation Following Tirzepatide Treatment: A Case Report.
- Slimming cardiac adipose tissue with liraglutide: pericardial is not epicardial fat (the LIRAFLAME substudy).
- Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers.
- Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.
- After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
- Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease.
- Impact of chemical structure, lipidation and formulation on luminal stability and intestinal absorption of GLP-1 analogues.
- Gateways to clinical trials.
- Vitreous hemorrhage in a patient on tirzepatide: Coincidence or drug induced?
- Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets.
- Treatment of obesity in spinal cord injury with tirzepatide: a case report.
- A Retrospective Analysis of Liraglutide (GLP-1 Agonist) Use in a Chinchilla (<i>Chinchilla lanigera</i>) Model of Auditory Blast Injury.
- Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.
- Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.
- A microfluidic in vitro method predicting the fate of peptide drugs after subcutaneous administration.
- A Case of GLP-1 Receptor Agonist-Induced Dysphoria and Aggression in a Patient With Underlying Major Depressive Disorder.
- Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder.
- Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.
- 68Ga-NODAGA-Exendin-4 PET/CT Findings in a Case of Metastatic Insulinoma With Refractory Hypoglycemia Controlled by 90Y Transarterial Radioembolization.
- Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis.
- Starvation ketoacidosis associated with tirzepatide use for weight loss in a non-diabetic East Asian woman: a case report.
- Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie.
- A review of survodutide: a new dual acting agonist.
- Liraglutide Effectiveness: Is There a Real-Word Clinical Benefit?
- Dulaglutide Effect on Proteins Associated With CKD Progression.
- The efficacyand safety of once weekly injectable semaglutide (Ozempic) among patients with Type 2 diabete sintertiary care hospital: A Retrospective Study.
- Semaglutide (Wegovy) for weight loss.
- [The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes].
- [Effects of glucagon-like peptide-1 on appetite and body weight: preclinical and clinical data].
- The role of combination therapy in type 2 diabetes in the post-ACCORD era.
- Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.
- Combination therapy of GLP-1 analogues and insulin: do the benefits outweigh the costs?
- Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs.
- GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practice.
- Algorithm-Based Common Microcirculatory Framework for Monitoring and Visualizing the Integrated Pancreatic Microcirculation in Type 2 Diabetes Mellitus Mice.
- [GLP-1 agonists: an overview].
- Retraction Note: Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways.
- Comparison table: Some drugs for weight management.
- Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial.
- An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus.
- Semaglutide: An emerging treatment option for patients with obesity related HFpEF.
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
- Semaglutide (Wegovy) for MASH.
- A cardiovascular indication for oral semaglutide (Rybelsus).